



# Global O-GlcNAc levels modulate transcription of the adipocyte secretome during chronic insulin resistance

Edith E. Wollaston-Hayden<sup>1,2</sup>, Ruth B. S. Harris<sup>3</sup>, Bingqiang Liu<sup>2</sup>, Robert Bridger<sup>1</sup>, Ying Xu<sup>2</sup> and Lance Wells<sup>1,2\*</sup>

<sup>1</sup> Complex Carbohydrate Research Center, University of Georgia, Athens, GA, USA

<sup>2</sup> Department of Biochemistry and Molecular Biology, University of Georgia, Athens, GA, USA

<sup>3</sup> Department of Physiology, Georgia Health Sciences University, Augusta, GA, USA

## Edited by:

Tony Lefebvre, CNRS/UMR 8576,  
University Lille 1, France

## Reviewed by:

Anne-Françoise Burnol, Cochin  
Institute, France  
Xiaoyong Yang, Yale University School  
of Medicine, USA

## \*Correspondence:

Lance Wells, Department of  
Biochemistry and Molecular Biology,  
Complex Carbohydrate Research  
Center, University of Georgia, 315  
Riverbend Road, Athens, GA 30602,  
USA  
e-mail: lwells@ccrc.uga.edu

Increased flux through the hexosamine biosynthetic pathway and the corresponding increase in intracellular glycosylation of proteins via O-linked  $\beta$ -*N*-acetylglucosamine (O-GlcNAc) is sufficient to induce insulin resistance (IR) in multiple systems. Previously, our group used shotgun proteomics to identify multiple rodent adipocytokines and secreted proteins whose levels are modulated upon the induction of IR by indirectly and directly modulating O-GlcNAc levels. We have validated the relative levels of several of these factors using immunoblotting. Since adipocytokines levels are regulated primarily at the level of transcription and O-GlcNAc alters the function of many transcription factors, we hypothesized that elevated O-GlcNAc levels on key transcription factors are modulating secreted protein expression. Here, we show that upon the elevation of O-GlcNAc levels and the induction of IR in mature 3T3-F442a adipocytes, the transcript levels of multiple secreted proteins reflect the modulation observed at the protein level. We validate the transcript levels in male mouse models of diabetes. Using inguinal fat pads from the severely IR *db/db* mouse model and the mildly IR diet-induced mouse model, we have confirmed that the secreted proteins regulated by O-GlcNAc modulation in cell culture are likewise modulated in the whole animal upon a shift to IR. By comparing the promoters of similarly regulated genes, we determine that Sp1 is a common *cis*-acting element. Furthermore, we show that the LPL and SPARC promoters are enriched for Sp1 and O-GlcNAc modified proteins during insulin resistance in adipocytes. Thus, the O-GlcNAc modification of proteins bound to promoters, including Sp1, is linked to adipocytokine transcription during insulin resistance.

**Keywords:** O-GlcNAc, insulin resistance, adipose tissue, adipocytokines, transcription

## INTRODUCTION

It is estimated that diabetes affects 8.3% of the United States population (1). Type 2 diabetes mellitus (T2DM) is characterized by both hyperinsulemia and hyperglycemia, which result from a combination of whole-body insulin resistance and pancreatic beta-cell dysfunction that leads to insulin insufficiency (2). T2DM can lead to a wide-range of severe and costly complications, such as blindness, kidney failure, stroke, and cardiovascular disease (3). The abundance of associated complications reflects the number of interrelated systems involved in T2DM pathogenesis (4).

White adipose tissue is an important mediator of energy homeostasis. In addition to its role as an energy storage depot, it acts as an endocrine organ by secreting adipocytokines, such as leptin and adiponectin. Adipocytokines can affect both local and distant tissue insulin sensitivity and energy homeostasis (5, 6). Obesity alters the ability of adipose tissue to properly express and secrete adipocytokines. Obesity, which affects more than 10% of adults world-wide, is the leading environmental risk factor for the development insulin resistance and T2DM (7–9). Importantly, several adipocytokines have been implicated in the development of insulin resistance and the pathogenesis of T2DM (10). The mechanism by

which adipocytes respond to the excess nutrient-flux during obesity and insulin resistance and alter the secretion of adipocytokines is not completely understood.

One way for cells to sense nutrient abundance and thereby alter their metabolism and gene expression is through the hexosamine biosynthetic pathway (HBP). In 1991, Marshall et al. first implicated the HBP in the development of insulin resistance (11). The HBP has been proposed to be a nutrient-flux sensor, since it utilizes 2–5% of intracellular glucose, and acts to limit the amount of glucose uptake by inducing insulin resistance (11). The end product of the HBP, uridine 5'-diphospho-*N*-acetylglucosamine (UDP-GlcNAc), is the sugar donor for the enzyme O-GlcNAc transferase (OGT), which transfers the O-GlcNAc post-translational modification onto serine or threonine residues of nuclear and cytoplasmic proteins (12–15). It has been demonstrated by many groups, including our own, that in multiple systems the elevation of O-GlcNAc levels is sufficient to induce insulin resistance (16–21).

The expression of several adipocytokines has been shown to be regulated at the level of transcription (22–26). Additionally, the transcription and secretion of several adipocytokines is modulated

by altered HBP flux (22, 27, 28). Transgenic mice overexpressing OGT in peripheral tissues have both glucose disposal defects and hyperleptinemia, suggesting that the O-GlcNAc modification is intricately tied to the development of insulin resistance and the regulation of adipocytokines (16).

We have recently used shotgun proteomics to identify multiple murine secreted proteins from adipocytes (adipocytokines) whose levels are modulated upon the induction of insulin resistance by indirectly and directly modulating O-GlcNAc levels (29). In this study, we investigate the transcriptional regulation of several of the secreted proteins identified by proteomics. We explore whether O-GlcNAc modified transcription factors are regulating these proteins, since several adipocytokines are known to be regulated at the level of transcription and O-GlcNAc has been demonstrated to modify and alter the function of many transcription factors (30, 31). Here, we show that these secreted factors are co-regulated in a mouse adipocyte cell line and two mouse models of insulin resistance. We demonstrate that the promoters of these genes contain a common *cis*-acting motif for Sp1. We determine that Sp1 is more heavily O-GlcNAc modified during insulin resistance. Finally, we determine that Sp1 and O-GlcNAc modified proteins are enriched on the LPL and SPARC promoters. Our findings suggest that the O-GlcNAc modification of proteins regulates adipocytokine transcription during chronic insulin resistance.

## MATERIALS AND METHODS

### MATERIALS AND REAGENTS

Tissue culture media, serum, and antibiotics were purchased from Gibco (Grand Island, NY, USA). 3-isobutyl-1-methylxanthine and dexamethasone were from Sigma (St. Louis, MO, USA). Recombinant insulin, human, was from Roche Diagnostics (Indianapolis, IN, USA). O-(2-acetamido-2-deoxy-D-glucopyranosylidene)amino *N*-phenyl carbamate (PUGNAc) was from Toronto Research Chemicals Inc. (North York, ON, USA). GlcNAc6S was a kind gift from Dr. Daan van Aalten (University of Dundee, Dundee, Scotland). Anti-Sp1 (PEP 2), anti-LPL (H-53), anti-Angiotensin I/II (N-10), anti-ERK-2 (C-14), normal sera, and agarose conjugated beads were from Santa Cruz Biotechnology (Santa Cruz, CA, USA). Anti-PEBP1 was from Novus Biologicals (Littleton, CO, USA). Anti-SPARC was from Abcam (Cambridge, MA, USA). Anti-O-GlcNAc (RL2) was from Enzo Life Sciences (Farmingdale, NY, USA). Anti-O-GlcNAc (CTD110.6) was previously generated in Dr. Gerald W. Hart's Laboratory (Johns Hopkins University, Baltimore, MD, USA). Dynabead Protein G was from Life Technologies (Carlsbad, CA, USA).

### CELL CULTURE AND TREATMENTS

3T3-F442a preadipocytes were maintained and differentiated as previously described (29, 32). On day 6 after the induction of differentiation, the adipocytes were maintained in the appropriate low (1.0 g/L) or high glucose (4.5 g/L) DMEM media containing 10% FBS, antibiotics, and vitamins with or without 100  $\mu$ M PUGNAc, 20 nM GlcNAc6S, or 100 nM insulin. After 24 h incubation, cells were washed either three times or five times (for media immunoblotting) with low or high glucose serum free media without antibiotics and vitamins. Following the rinses, cells were

incubated for 16 h in the appropriate low or high glucose media without serum, antibiotics, and vitamins and with or without 100  $\mu$ M PUGNAc, 20 nM GlcNAc6S, or 1 nM insulin. After the incubation, the conditioned media was carefully collected, filtered, and buffer exchanged as previously described (29). The remaining cells were washed two times with ice cold PBS and then harvested by scraping and stored at  $-80^{\circ}\text{C}$  until further analysis.

### ANIMALS

Animal procedures were approved by the Institutional Animal Care and Use Committee of the University of Georgia. Animals were group housed with a 12-h light, 12-h dark cycle. Inguinal and retroperitoneal fat tissues from 12-week-old-male C57BL/6J wt (wt), C57BL/6J *db/db* (6J), and C57BL/3J *db/db* (3J) mice were isolated along with serum. Mice were fed *ad libitum* normal rodent chow. After sacrifice by decapitation, the inguinal fat was weighed, snap frozen, and stored at  $-80^{\circ}\text{C}$  until transcript analysis. Both the 3J and 6J mice had both inguinal and retroperitoneal fat masses three times greater than the wildtype littermates as well as elevated serum glucose levels ( $>1.5\times$ ) and insulin levels ( $>5\times$ ) with the 3J mice having higher levels than 6J mice. For the diet-induced insulin resistance experiment, young ( $\sim 9$  weeks) C57BL/6 male mice were purchased from The Jackson Laboratory (Bar Harbor, ME, USA). Both treatment groups were fed *ad libitum* normal rodent chow and water. The mice in the high fat high sucrose (HFHS) treatment group were given free access to a 30% sucrose solution and lard in addition to their normal chow and water. After week 1, 2, and 3 of treatment, an insulin sensitivity test (ITT) was performed on a pair of mice closest to the average weight of each treatment group. The insulin sensitivity test was performed as previously described (33). Weights were recorded every week. After 3 weeks of treatment, six mice from each treatment group were sacrificed by decapitation. Trunk blood was collected for the measurement of serum insulin using a LINCO rat insulin RIA kit (EMD Millipore Corporation, Billerica, MA, USA). The liver and four fat pads (inguinal, epididymal, mesenteric, and retroperitoneal) were weighed, snap frozen, and stored at  $-80^{\circ}\text{C}$  until transcript analysis.

### CELL LYSATES, WESTERN BLOTTING, AND IMMUNOPRECIPITATION

For immunoprecipitations and anti-O-GlcNAc Western blots, 3T3-F442a cell pellets were lysed in 20 mM Tris pH 7.5, 150 mM NaCl, 1 mM EDTA, 1% NP-40, 1:100 protease inhibitor cocktail set V, EDTA-free (Calbiochem), and 1  $\mu$ M PUGNAc. Protein concentration was determined using the Pierce BCA Protein Assay Kit (Thermo Scientific, Rockford, IL, USA). The CTD110.6 Western blots were performed essentially as described (34). Immunoprecipitations were carried out at  $4^{\circ}\text{C}$  overnight using anti-Sp1 or normal rabbit IgG with 750  $\mu$ g of precleared protein lysate. Immuno-complexes were collected using Protein A/G-PLUS agarose beads for 2 h. Beads were washed four times with a modified RIPA buffer (20 mM Tris pH 7.5, 150 mM NaCl, 1 mM EDTA, 1% NP-40, 0.1% SDS) and one time with a high salt modified RIPA buffer (same as above except 500 mM NaCl). Proteins were eluted by boiling beads in  $1\times$  Laemmli buffer and then transferred to a fresh tube for Western blotting. For the concentrated media Western blots, the protein concentration of the concentrated 3T3-F442a

media was determined using the Bradford method and verified by Coomassie staining. Equal amounts of protein were separated by SDS-PAGE with Tris-HCl precast minigels (Bio-Rad, Hercules, CA, USA) and transferred to poly(vinylidene difluoride) (PVDF) membranes (for concentrated media) or nitrocellulose membranes (for immunoprecipitations) for Western blot analysis. After blocking for at least 1 h, membranes were incubated with the appropriate primary antibody overnight at 4°C. Membranes were incubated with the appropriate horseradish peroxidase-coupled secondary antibodies for 1 h, followed by extensive washing and Pierce ECL detection. ImageJ was used for densitometry (35).

### CHROMATIN IMMUNOPRECIPITATION

Chromatin Immunoprecipitations were performed as in the Millipore EZ-ChIP kit with some modifications. Day 8 adipocytes were washed once with room temperature PBS and then crosslinked by adding 1% formaldehyde in PBS and incubating for 10 min. The adipocytes were washed three times with cold PBS and then harvested by scraping. The adipocytes were resuspended in hypotonic lysis buffer (20 mM Tris-HCl, pH 7.5, 10 mM NaCl, 3 mM MgCl<sub>2</sub>, 1:100 Calbiochem protease inhibitor) and incubated on ice then dounce homogenized. The nuclei were collected by centrifugation and then resuspended in SDS lysis buffer. DNA was sheared to between 200 and 1000 base pair fragments using a Misonix S-4000 sonicator. Protein concentration was quantified using the Pierce BCA Protein Assay Kit. One hundred micrograms of chromatin was used per immunoprecipitation. Sonicated chromatin was diluted 1:10 with dilution buffer and precleared using Protein A/G-PLUS agarose, normal goat IgG, and sheared salmon sperm DNA (ssDNA) (Ambion). Three percent of the sample was saved as Input. One microgram of anti-Sp1, anti-O-GlcNAc (RL2), or normal IgG was used for the immunoprecipitation. Immuno-complexes were collected for 1 h using Protein G Dynabeads that were blocked with ssDNA and BSA (New England Biolabs). The Dynabeads were washed five times and then eluted with 1% SDS and 0.1 M NaHCO<sub>3</sub>. The elutions were decrosslinked at 65°C overnight with NaCl and RNase A (Ambion). After Proteinase K treatment (New England Biolabs), samples were purified by a Phenol-Chloroform extraction followed by ethanol precipitation overnight at -20°C using glycogen as a carrier. Precipitated DNA was resuspended in 3 mM Tris-HCl pH 8.0, 0.1 mM EDTA. qPCR was performed using primers for the proximal mouse SPARC and LPL promoter Sp1-binding sites. Sequences of primers were SPARC primers 5'-AGGCAAGTTCCTCGCTGGCT-3' (forward) and 5'-AGACACCCTGGCCCCACCTG-3' (reverse) and LPL primers 5'-CCTTCTTCTCGCTGGCACCGTT-3' (forward) and 5'-GGGCAGAACAGTTACAAGGGGCA-3' (reverse). The fold enrichment was calculated for each primer/antibody/treatment combination. First the normalized ChIP  $C_t$  values were calculated:  $\Delta C_{t(\text{normalized ChIP})} = \{C_{t(\text{ChIP})} - [C_{t(\text{Input})} - \text{Log}_2(\text{Input Dilution Factor})]\}$ . The % Input was calculated: % Input =  $2^{-\Delta C_{t(\text{normalized ChIP})}}$ . Lastly, fold enrichment was calculated: fold Enrichment = (% Input of antibody/% Input of IgG).

### GENE EXPRESSION ANALYSIS

RNA was isolated from 3T3-F442a cell pellets and inguinal fat pads using the Invitrogen PureLink Micro-to-Midi RNA Total RNA

Purification System with Trizol reagent and on column DNase I treatment. The Invitrogen Superscript III First-Strand Synthesis System for RT-PCR was used to synthesize cDNA (Life Technologies, Carlsbad, CA, USA). All RT-qPCR primers were obtained from Qiagen QuantiTect Primer Assays and used with Qiagen QuantiTect SYBR Green PCR Kits (Qiagen, Valencia, CA, USA). ChIP-qPCR primers were used with iQ SYBR Green Supermix (Bio-Rad, Hercules, CA, USA). Amplifications were performed in a Bio-Rad 96-well iCycler or myiQ real-time detection system using the appropriate QuantiTect or iQ SYBR Green cycling protocol. Changes in target gene expression were normalized to TATA box binding protein (Tbp) and ribosomal protein L4 expression (Rpl4). Relative transcript levels were calculated using the  $\Delta\Delta C_t$  method (36). Normoglycemic transcript levels were set to 100.

### MOTIF ANALYSIS

Promoter sequences containing 500 bp upstream of the transcriptional start site were collected for human, mouse, and rat using the UCSC Genome Browser (37). No rat ortholog was found for Quiescin Q6. The human set was used as the main set and was supported by the mouse and rat ortholog sets. Three genes that were identified in the rodent adipocyte secretome but did not change in expression during insulin resistance were used as the negative set for human, mouse, and rat (29). Seven motif finding tools were used for primary motif finding: AlignACE (38), Bioprosppector (39), CONSENSUS(40), CUBIC (41), MDscan (42), MEME (43), and BOBRO (44). For each candidate, a position weight matrix and scoring matrix were generated (Table S1 in Supplementary Material). Corresponding transcription factor binding motifs were determined by analyzing the position weight matrix with TOM-TOM (45). Conserved transcription factor binding motifs were confirmed using human and mouse sequences in rVISTA 2.0 (46).


### STATISTICAL ANALYSIS

All statistics were performed using the General Linear Model Analysis of Variance [GLM AOV, Statistix (Statistix 10.0, 2010, Tallahassee, FL, USA)]. Error bars represent the SEM of independent experiments. *P*-values under 0.05 were considered significant and represented using an \* in all figures. All experiments shown were replicated three to five times.

## RESULTS

### THE INDUCTION OF INSULIN RESISTANCE IN 3T3-F442a ADIPOCYTES MODULATES SECRETED STEADY-STATE PROTEIN LEVELS AND TRANSCRIPT LEVELS IN THE SAME MANNER

3T3-F442a preadipocytes were differentiated into mature adipocytes before experimental treatments. Mature adipocytes were either maintained in insulin sensitive conditions [low glucose (LG)] or shifted to insulin resistant conditions by the classical treatment of high glucose and chronic insulin (HG + INS) to generate hyperglycemia and hyperinsulemia or by treatment with low glucose and the OGA inhibitors PUGNAc (LG + PUGNAc) or GlcNAcstatin (LG + GlcNAcstatin) to more specifically elevate global O-GlcNAc levels. **Figure 1A** shows that all insulin resistant conditions generated elevated global O-GlcNAc levels as evaluated by immunoblotting with an O-GlcNAc specific antibody. Previously, our group used shotgun proteomics to characterize the secreted proteome of rodent adipocytes and to identify



multiple proteins whose levels are modulated upon the induction of insulin resistance by indirectly and directly modulating O-GlcNAc levels in rodent adipocytes as described above (29). **Figure 1B** shows a shortened list of adipocytokines whose protein expression was found to be positively regulated by the induction of insulin resistance using quantitative proteomics in our previous studies. Here, we validated the relative levels of several of these secreted proteins using immunoblotting as an orthogonal method. 3T3-F442a adipocyte conditioned media from each treatment group was concentrated and buffer exchanged before immunoblotting with selected antibodies. **Figure 1C** shows that the regulation observed by quantitative proteomics is recapitulated by immunoblotting as an independent method. Since adipocyte insulin resistance was induced by either indirectly (HG + INS) or directly (LG + PUGNAc) altering O-GlcNAc levels, it is likely that O-GlcNAc is modulating the secretion of these adipocytokines. Since the secretion of many of the adipocytokines studied thus far is regulated at the level of transcription (22–26) and O-GlcNAc has been shown to modify and alter the function of many transcription

factors (47), we hypothesized that the elevation of O-GlcNAc levels was regulating many of the identified adipocytokines at the level of transcription. **Figure 1D** shows that upon the elevation of O-GlcNAc levels and the induction of insulin resistance in 3T3-F442a adipocytes, the steady-state transcript levels of many of the identified secreted proteins, as measured by qPCR, reflect the modulation observed at the protein level.

#### THE INDUCTION OF INSULIN RESISTANCE MODULATES SECRETED PROTEIN STEADY-STATE TRANSCRIPT LEVELS IN A GENETIC INSULIN RESISTANT MOUSE MODEL

The mouse preadipocyte cell lines are a very useful system for studying adipocyte biology; however, their ability to secrete proteins at the high levels measured *in vivo* is impaired in many cases (48). Additionally, the complex paracrine interactions between adipocytes and the stromal-vascular cell fraction that comprises adipose tissue as well as the signaling between tissues in a whole animal are lost in adipocyte cell lines *in vitro* (49). Therefore, the regulation of adipocytokine transcript levels upon the induction of

insulin resistance was examined in a biologically relevant mouse model. The inguinal fat pads from severely insulin resistant 12-week-old male leptin receptor mutant (*db/db*) mice were used for transcript analysis. *db/db* mice produce leptin but fail to respond to it. The C57BL/6J *db/db* (6J) mice produce only the short-form leptin receptors (Ob-Ra, Ob-Rc, Ob-Rd) and the circulating form leptin receptor (Ob-Re) but not the long signaling form of the receptor (Ob-Rb). The C57BL/3J *db/db* (3J) mice produce only the circulating form leptin receptor (Ob-Re) (50). **Figure 2** shows the inguinal fat pad transcript levels in the *db/db* mouse models vary significantly from the *wt* mice and reflect the modulation shown at the transcript and protein levels in the 3T3-F442a adipocytes. All of the transcripts were elevated with the exception of the control gene, adipsin. Adipsin transcript levels have been shown to be downregulated in many models of rodent obesity (51).


### THE INDUCTION OF INSULIN RESISTANCE MODULATES STEADY-STATE TRANSCRIPT LEVELS IN A DIET-INDUCED IR MOUSE MODEL


Evidence suggests that T2DM develops from a combination of genetic and environmental factors but the relative contribution of each is unclear (52). A monogenic genetic mouse model (*db/db*) does not represent the true genetic heterogeneity that is present in most cases of human T2DM (53). In addition, the genetic defect is in an adipocytokine pathway, which could lead to potentially confounding effects for this experiment (54). To address these concerns, a diet-induced insulin resistant mouse model was developed by feeding *ad libitum* sucrose and lard (HFHS) to approximately 9-week-old C57BL/6 mice as described in Section “Materials and Methods.” After 3 weeks of treatment, the live weight as well as the wet weight of the inguinal, epididymal, mesenteric, and retroperitoneal fat pads was significantly increased in the HFHS mice compared to the mice on the normal chow diet (Figure S1A in

Supplementary Material). The mice on the HFHS diet had elevated glucose levels and an attenuated response to insulin (Figure S1B in Supplementary Material). In addition, the mice displayed significantly elevated insulin levels (Figure S1C in Supplementary Material). After 3 weeks on the HFHS diet, the mice displayed mild insulin resistance and obesity so the inguinal fat pads were used for transcript analysis. Since the diet-induced insulin resistant mice were mildly obese and insulin resistant, we would expect the adipsin levels to only change slightly in contrast to the *db/db* mice, which were extremely obese and insulin resistant. **Figure 3** shows the transcript levels were significantly elevated in the HFHS mice inguinal fat pads for all genes excluding adipsin. The diet-induced insulin resistant mice transcript levels reflect the modulation shown at the transcript level in the *db/db* mouse fat pads and at the transcript and protein levels in the 3T3-F442a adipocytes. **Table 1** shows the relative increase in transcript levels in the insulin resistant mice (HFHS and 6J) compared to the transcript levels of the insulin sensitive mice (N and wt), which are set to 100%. Given that transcript level regulation is consistent for both insulin resistant mouse models, the transcript regulation observed in cell culture during insulin resistance is validated.

### SP1 IS A COMMON CIS-ACTING ELEMENT FOR THE ADIPOCYTOKINE PROMOTERS AND THE O-GLcNAc MODIFICATION OF SP1 IS ALTERED DURING INSULIN RESISTANCE

We hypothesized that a common transcription factor or cofactor was responding to the elevation of O-GlcNAc levels and altering the transcription of the observed secreted proteins. Multiple complementary motif finding programs were used to analyze the same set of orthologous proximal promoters in order to find a more accurate set of regulatory motifs. Human, mouse, and rat promoters were used to identify conserved motifs, with the hope





**FIGURE 3 | Diet-induced insulin resistant mice display altered adipocytokine steady-state transcript levels.** Inguinal fat pads from C57BL/6 mice fed normal chow (N) ( $n = 4$ ) or a high fat, high sucrose (HFHS)

( $n = 3$ ) diet for 3 weeks were used for transcript analysis by qPCR. Data are presented so that 100% represents the transcript level in the insulin responsive condition (N). \* $P < 0.05$ .

**Table 1 | Secreted protein transcript levels elevated in mouse models of insulin resistance.**

Mouse model	LPL	SPARC	Cathepsin B	Serpin A	Quiescin Q6
Insulin sensitive	100	100	100	100	100
Diet-induced	185	224	146	139	237
Genetic	316	511	379	760	425

that the most important regulatory motifs would be under stronger evolutionary pressure (Figure 4A) (55). Twenty-four common putative regulatory motifs were identified using motif analysis programs as described in Section “Materials and Methods” (Table S1 in Supplementary Material). The putative regulatory motifs were compared to known transcription factor binding motifs. The Sp1-binding motif was found to match putative regulatory motif 3 (Figure 4B). The conservation of the Sp1 sites between human and mouse promoters was verified using rVista 2.0. Sp1 is relevant to adipocytokine transcription since it is a target of the insulin signaling cascade and many promoters of genes regulated during insulin resistance have Sp1 motifs (56–61). In addition, Sp1 is known to be dynamically modified by O-GlcNAc (47). Sp1 O-glycosylation is reported to be elevated in the liver, kidney, and adipose tissue of *db/db* mice (62). Many studies have associated the altered O-GlcNAc modification of Sp1 with altered transcriptional activation of target genes (63–68). Figure 4C shows that immunoprecipitated Sp1 has greater O-GlcNAc modification during insulin resistance in 3T3-F442a adipocytes. Both direct (LG + GlnAcstatin) and indirect (HG + INS) modulation of O-GlcNAc levels trended toward elevated Sp1 O-GlcNAc modification although only the GlnAcstatin reached statistical significance.


The more modest O-GlcNAc modification seen in the HG + INS condition was most likely due to the more modest increase in global O-GlcNAc levels (Figure 1A).

### SP1 AND O-GLCNAc MODIFIED PROTEINS ARE ENRICHED ON THE PROXIMAL SPARC AND LPL PROMOTERS DURING INSULIN RESISTANCE

We noticed that two of the identified motif three positions on the promoters corresponded with known biologically relevant Sp1-binding sites for LPL and SPARC. Since these sites are reported to be important for transcriptional activation, we wanted to determine whether Sp1 and O-GlcNAc modified proteins were enriched at these sites during insulin resistance in 3T3-F442a adipocytes. ChIP was performed with Sp1 and O-GlcNAc specific antibodies. Enrichment on the promoters was determined by analyzing purified DNA using qPCR with primers designed to amplify the region containing the Sp1-binding motif on either the LPL or SPARC promoter. Figure 5 shows both of the promoter regions showed significant enrichment of both Sp1 and O-GlcNAc modified proteins during insulin resistant conditions. These results suggest that the elevation of global O-GlcNAc levels, either directly or indirectly, leads to increased O-GlcNAc modification of Sp1 and increased Sp1 enrichment on the SPARC and LPL proximal promoters. Since the O-GlcNAc antibody will bind any protein modified with O-GlcNAc, the enrichment of O-GlcNAc on the LPL and SPARC promoters could be due to O-GlcNAc modified Sp1 or potentially other O-GlcNAc modified proteins.

### DISCUSSION

White adipose tissue plays an important role in maintaining energy homeostasis by mediating lipid flux and altering the secretion of adipocytokines. Adipocytokines can act in an autocrine, paracrine,




or endocrine manner to regulate a variety of processes, including energy homeostasis (5). Genetic mouse models showing that the induction of insulin resistance in white adipose tissue induces whole-body insulin resistance have highlighted the importance of adipocytokines during insulin resistance (69–71). In addition, adipocytokines are implicated in many of the complications leading to and resulting from T2DM, especially the tissue remodeling during nephropathy, cardiovascular disease, and obesity (72).

Many of the secreted proteins we studied are extracellular matrix (ECM) modulators and associated with inflammatory states. SPARC is a modulator of cell – ECM interactions and has diverse roles in osteogenesis, angiogenesis, fibrosis, tumorigenesis, and adipogenesis (73). Cathepsin B is associated with ECM degradation, apoptosis, and inflammation (74). Serpina is an acute phase response protein that is involved in inflammation (75). Quiescin Q6 is upregulated in pancreatic cancer and may promote tumor cell invasion by upregulating matrix metalloproteinases (76,77). Involvement in tumorigenesis is another common theme for these adipocytokines. During obesity, extensive remodeling is required for the expansion of fat pads (78). These ECM modulators may play an important role in local tissue remodeling. Obese

adipose tissue is associated with an inflammatory response, which may also be mediated in part by these adipocytokines (78–83).

In this study, we have attempted to better define the relationship between O-GlcNAc modification and adipocyte-secreted protein transcription during insulin resistance. Several studies have suggested that leptin and adiponectin are regulated primarily at the level of transcription in adipocytes (22–25, 84). We investigated whether the secreted factors that we identified by quantitative proteomics were similarly regulated after confirming the elevation via an orthogonal method, Western blotting, for several of these secreted proteins. We have also recently evaluated many of these secreted factors in human adipose tissue with similar findings (85). We found that the induction of insulin resistance in mouse adipocytes elevated transcript levels in the same manner as protein levels for several of the secreted proteins identified by proteomics (Figure 1). Although a role for the transcriptional regulation of adipocytokine secretion has been established for SPARC (86), there are conflicting reports for LPL (87–90), and it was not known whether Cathepsin B, Quiescin Q6, and Serpina were transcriptionally regulated in adipocytes. In addition, the biological relevance of the transcriptional upregulation of the proteins



during insulin resistance was verified using both a genetic and diet-induced mouse model of insulin resistance (Figures 2 and 3).

Several studies have suggested that adipocytokine expression is regulated by the HBP and O-GlcNAc. Infusions of metabolites that increased HBP flux into rats increased leptin expression (22, 91). Both GFAT and OGT transgenic mice displayed hyperleptinemia (16, 27, 28). GFAT transgenic mice also displayed decreased adiponectin levels (28). In primary human adipocytes and 3T3-L1 mouse adipocytes, HBP flux was shown to correlate with leptin expression (27, 92). Although many studies have manipulated the HBP, studies that manipulate O-GlcNAc levels more directly and

examine adipocytokine expression have been lacking. We found that both the direct modulation of O-GlcNAc levels by the addition of OGA inhibitors and the indirect modulation of O-GlcNAc levels by hyperglycemia and chronic hyperinsulinemia in mouse adipocytes elevated transcript levels in the same manner as protein levels (Figure 1). It was not known whether inducing insulin resistance solely by raising global O-GlcNAc levels would regulate these secreted proteins at the level of transcription.

It is reasonable to assume that co-regulated genes have a similar upstream regulator. Since we found that the expression of these proteins was similarly regulated by both classical insulin resistance and by solely raising global O-GlcNAc levels, we hypothesized that O-GlcNAc was a regulator. O-GlcNAc has been proposed to be a “nutrient sensor” because the levels of the end product of the HBP, UDP-GlcNAc, are regulated by the flux of glucose, uridine, glutamine, and FFA’s (93, 94). OGT is responsive to physiological levels of UDP-GlcNAc, so increased HBP flux results in globally elevated levels of O-GlcNAc modification (95). The regulation of OGT is complex and still being elucidated but it is clear that it has a preference for certain proteins and sites and does not universally add O-GlcNAc to all proteins (96–98). A large body of literature has shown that the O-GlcNAc modification plays an important role in transcriptional regulation. O-GlcNAc modifies transcription factors and cofactors, RNA Pol II, chromatin remodelers, and has even been identified as part of the histone code. O-GlcNAc modification of proteins can affect protein stability, protein–protein interactions, chromatin remodeling, transcriptional initiation and elongation, DNA binding, and localization (47, 99).

The secreted factors were regulated at the level of transcription, so we looked for common transcription factor binding motifs. After determining that Sp1 was a common *cis*-acting motif for these genes, we found that the O-GlcNAc modification of Sp1 trended toward an increased level during insulin resistance in mouse adipocytes (Figure 4). Sp1 has been implicated in the transcriptional regulation of LPL, SPARC, Cathepsin B, and SerpinA.

A role for Sp1 as a regulator of SPARC transcription has been established in transformed cells. The proximal promoter of SPARC contains several modified GC-boxes that are binding sites for Sp1 and/or Sp3. Sp1 and/or Sp3 are required for SPARC transcriptional activation in chickens, mice, and human beings (100–102). In chick embryonic fibroblasts, *v-Jun* represses SPARC promoter activation and initiates cell transformation by targeting the minimal promoter region. It was shown that *v-Jun* does not bind this DNA region directly but binds Sp1 and/or Sp3 to target promoter activation (101). *c-Jun* activates SPARC transcription in human MCF7 cells through the activation of Sp1 (100). In mammary carcinoma, Brg-1, a SWI/SNF chromatin remodeling complex ATPase, was shown to interact with Sp1 to activate SPARC transcription (102). Sp1’s involvement in SPARC transcription in adipocytes has not previously been described.

Several studies have associated Sp1 and/or Sp3 with LPL transcriptional regulation. Interferon- $\gamma$  (IFN $\gamma$ ) decreases macrophage LPL transcription by decreasing Sp3 protein levels and Sp1 DNA binding to sites in the 5’ UTR, which is mediated by casein kinase 2 (CK2) and Akt (103, 104). Transforming growth factor- $\beta$  (TGF- $\beta$ ) represses macrophage LPL transcription through Sp1 and/or Sp3 sites in the 5’-UTR (105). Sp1 and/or Sp3 also bind an

evolutionarily conserved CT element (−91 to −83), also known as a GA box, in the proximal promoter. Sterols regulate LPL through a SRE site that is close to the CT element (89, 106). A T(−93)G SNP that is close to the CT element has been associated with a predisposition to obesity and familial combined hyperlipidemia in some studies in human beings. The minor allelic frequency is highly variable for difference ethnic populations and the SNP effect may be influenced by the synergistic effects of a Asp9Asn and T(−93)G haplotype that is present in some populations (107–110). People with both the Asp9Asn and T(−93)G mutations have been shown to have an increased risk of cardiac disease and decreased LPL activity in some studies (111–113). In the South African black population, the SNP was associated with mildly lower triglyceride levels and was associated with higher promoter activation in smooth muscle cells (108, 114). This is in contrast to other studies, which show that the mutation decreases Sp1 and/or Sp3 DNA binding leading to lowered transcriptional activation (106, 107, 109, 110). Sterol regulatory element-binding protein (SREBP) was found to act synergistically with Sp1 to activate the promoter in macrophages. Mutation of the CT element is also reported to decrease promoter reporter activity in 3T3-F442a pre-adipocytes (115). The importance of these Sp1/Sp3 binding sites has not been previously explored in mature adipocytes.

Both Sp1 and O-GlcNAc modified proteins were found to be significantly enriched in the region of the conserved Sp1 site on both the LPL and SPARC promoters (Figure 5). In our experiments in mature mouse adipocytes, Sp1 is most likely facilitating transcriptional activation. The studies described above have begun to shed light on the role of O-GlcNAc in modulating adipocytokine transcription through the modification of Sp1. Although Sp1 is ubiquitously expressed and often thought of as a housekeeping transcription factor, the diversity of Sp1 post-translational modifications and the wide-range of interaction partners can fine tune Sp1 activity in a context specific manner (116). Sp1 is subject to many forms of post-translational modification including phosphorylation, acetylation, sumoylation, ubiquitylation, and glycosylation. The sites of phosphorylation on Sp1 can either increase or decrease Sp1 DNA binding and transcriptional activation (117). Glycosylation can affect Sp1 stability, protein–protein interactions, DNA binding, degree of phosphorylation, and localization (47). These other modifications as well as the recruitment of other proteins to the promoters may explain the differences between HG + INS and LG + GNS. Sp1 has at least eight sites of O-GlcNAc modification, but the specific roles of each site is still being elucidated (118). Five sites of modification have been mapped to the DNA binding domain, and the mutation of these sites can disrupt Sp1 transcriptional activation in hepatocytes (62, 68). O-GlcNAc modification of the Sp1 activation domain inhibits Sp1 transactivation (64, 119). Since O-GlcNAc acts as a nutrient-flux sensor, many studies manipulate the glycosylation of Sp1 by manipulating nutrient flux. Studies using glycosylation site-specific Sp1 mutants would help to clarify the specific role of O-GlcNAc modification; however, determining the action of a specific glycosylation site could be complicated by the complex interplay between phosphorylation and O-GlcNAc modification as well as the presence of several other O-GlcNAc sites. In addition, site-specific Sp1 studies in adipocytes would be challenging since adipocytes are

notoriously difficult to transfect. Other O-GlcNAc modified proteins could also be modulating the adipocytokine transcription since the O-GlcNAc enrichment on the promoters could be due to proteins other than Sp1. ChIP-reChIP would help to determine, which proteins are in complex on the promoters.

In conclusion, these experiments serve to identify a possible mechanism by which adipocytes respond to insulin resistance and regulate the expression of adipocytokines. Future work is aimed at identifying the specific function of the O-GlcNAc modification on Sp1 during insulin resistance in adipocytes. In addition, the mechanism of adipocytokine transcriptional upregulation in animal models should be investigated. Understanding the transcriptional regulation of adipocytokines by O-GlcNAc may provide therapeutic targets for normalizing the expression of adipocytokines during obesity and T2DM.

## ACKNOWLEDGMENTS

We thank members of the Wells' laboratory past and present for their helpful discussions and review of this manuscript. We thank Dr. Paul M. Cline for his assistance with statistical analysis. We thank Dr. Daan van Aalten for supplying us with GlcNAcstatin. This work is supported by an American Heart Association National Scientific Development Grant (L.W.) and the NIDDK/NIH (R01DK075069, LW).

## SUPPLEMENTARY MATERIAL

The Supplementary Material for this article can be found online at <http://www.frontiersin.org/Journal/10.3389/fendo.2014.00223/abstract>

**Figure S1 | Characterization of the diet-induced IR mouse model. (A)** After 3 weeks on either the HFHS diet ( $n=6$ ) or normal diet ( $n=6$ ), mice were weighed, sacrificed, and the liver and four fat pads were dissected and weighed. Data are presented so that 100% represents the weight of the normal diet mice. **(B)** Insulin sensitivity test was performed as in Section "Materials and Methods." **(C)** Trunk blood was used for an Insulin RIA. \* $P < 0.05$ .

## Table S1 | Common motifs for adipocytokine promoters.

## REFERENCES

1. Prevention CFDC. *National Diabetes Fact Sheet: National Estimates and General Information on Diabetes and Prediabetes in the United States*. Atlanta: US Department of Health and Human Services (2011).
2. Kahn SE, Hull RL, Utzschneider KM. Mechanisms linking obesity to insulin resistance and type 2 diabetes. *Nature* (2006) **444**:840–6. doi:10.1038/nature05482
3. Brownlee M. The pathobiology of diabetic complications: a unifying mechanism. *Diabetes* (2005) **54**:1615–25. doi:10.2337/diabetes.54.6.1615
4. Hotamisligil GS. Inflammation and metabolic disorders. *Nature* (2006) **444**:860–7. doi:10.1038/nature05485
5. Ahima RS, Lazar MA. Adipokines and the peripheral and neural control of energy balance. *Mol Endocrinol* (2008) **22**:1023–31. doi:10.1210/me.2007-0529
6. Rosen ED, Spiegelman BM. What we talk about when we talk about fat. *Cell* (2014) **156**:20–44. doi:10.1016/j.cell.2013.12.012
7. Kilmer G, Roberts H, Hughes E, Li Y, Valluru B, Fan A, et al. Surveillance of certain health behaviors and conditions among states and selected local areas – behavioral risk factor surveillance system (BRFSS), United States, 2006. *MMWR Surveill Summ* (2008) **57**:1–188.
8. Ahima RS. Digging deeper into obesity. *J Clin Invest* (2011) **121**:2076–9. doi:10.1172/JCI58719
9. Organization WH. *Obesity and Overweight*. WHO Media centre (2012). Available from: <http://www.who.int/mediacentre/factsheets/fs311/en/index.html>

10. Havel PJ. Update on adipocyte hormones: regulation of energy balance and carbohydrate/lipid metabolism. *Diabetes* (2004) **53**(Suppl 1):S143–51. doi:10.2337/diabetes.53.2007.S143
11. Marshall S, Bacote V, Traxinger RR. Discovery of a metabolic pathway mediating glucose-induced desensitization of the glucose transport system. Role of hexosamine biosynthesis in the induction of insulin resistance. *J Biol Chem* (1991) **266**:4706–12.
12. McClain DA. Hexosamines as mediators of nutrient sensing and regulation in diabetes. *J Diabetes Complications* (2002) **16**:72–80. doi:10.1016/S1056-8727(01)00188-X
13. Wells L, Vosseller K, Hart GW. A role for N-acetylglucosamine as a nutrient sensor and mediator of insulin resistance. *Cell Mol Life Sci* (2003) **60**:222–8. doi:10.1007/s000180300017
14. Bond MR, Hanover JA. O-GlcNAc cycling: a link between metabolism and chronic disease. *Annu Rev Nutr* (2013) **33**:205–29. doi:10.1146/annurev-nutr-071812-161240
15. Hardiville S, Hart GW. Nutrient regulation of signaling, transcription, and cell physiology by O-GlcNAcylation. *Cell Metab* (2014) **20**:208–13. doi:10.1016/j.cmet.2014.07.014
16. McClain DA, Lubas WA, Cooksey RC, Hazel M, Parker GJ, Love DC, et al. Altered glycan-dependent signaling induces insulin resistance and hyperleptinemia. *Proc Natl Acad Sci U S A* (2002) **99**:10695–9. doi:10.1073/pnas.152346899
17. Vosseller K, Wells L, Lane MD, Hart GW. Elevated nucleocytoplasmic glycosylation by O-GlcNAc results in insulin resistance associated with defects in Akt activation in 3T3-L1 adipocytes. *Proc Natl Acad Sci U S A* (2002) **99**:5313–8. doi:10.1073/pnas.072072399
18. Parker GJ, Lund KC, Taylor RP, McClain DA. Insulin resistance of glycogen synthase mediated by o-linked N-acetylglucosamine. *J Biol Chem* (2003) **278**:10022–7. doi:10.1074/jbc.M207787200
19. Arias EB, Kim J, Cartee GD. Prolonged incubation in PUGNAc results in increased protein O-linked glycosylation and insulin resistance in rat skeletal muscle. *Diabetes* (2004) **53**:921–30. doi:10.2337/diabetes.53.4.921
20. Dentin R, Hedrick S, Xie J, Yates J III, Montminy M. Hepatic glucose sensing via the CREB coactivator CRTC2. *Science* (2008) **319**:1402–5. doi:10.1126/science.1151363
21. Yang X, Ongusaha PP, Miles PD, Havstad JC, Zhang F, So WV, et al. Phosphoinositide signalling links O-GlcNAc transferase to insulin resistance. *Nature* (2008) **451**:964–9. doi:10.1038/nature06668
22. Wang J, Liu R, Hawkins M, Barzilai N, Rossetti L. A nutrient-sensing pathway regulates leptin gene expression in muscle and fat. *Nature* (1998) **393**:684–8. doi:10.1038/31474
23. Kurata A, Nishizawa H, Kihara S, Maeda N, Sonoda M, Okada T, et al. Blockade of angiotensin II type-1 receptor reduces oxidative stress in adipose tissue and ameliorates adipocytokine dysregulation. *Kidney Int* (2006) **70**:1717–24. doi:10.1038/sj.ki.5001810
24. Nozaki M, Fukuhara A, Segawa K, Okuno Y, Abe M, Hosogai N, et al. Nitric oxide dysregulates adipocytokine expression in 3T3-L1 adipocytes. *Biochem Biophys Res Commun* (2007) **364**:33–9. doi:10.1016/j.bbrc.2007.09.084
25. Yuan G, Chen X, Ma Q, Qiao J, Li R, Li X, et al. C-reactive protein inhibits adiponectin gene expression and secretion in 3T3-L1 adipocytes. *J Endocrinol* (2007) **194**:275–81. doi:10.1677/JOE-07-0133
26. Szalowska E, Dijkstra M, Elferink MG, Weening D, De Vries M, Bruinenberg M, et al. Comparative analysis of the human hepatic and adipose tissue transcriptomes during LPS-induced inflammation leads to the identification of differential biological pathways and candidate biomarkers. *BMC Med Genomics* (2011) **4**:71. doi:10.1186/1755-8794-4-71
27. McClain DA, Alexander T, Cooksey RC, Considine RV. Hexosamines stimulate leptin production in transgenic mice. *Endocrinology* (2000) **141**:1999–2002. doi:10.1210/endo.141.6.7532
28. Hazel M, Cooksey RC, Jones D, Parker G, Neidigh JL, Witherbee B, et al. Activation of the hexosamine signaling pathway in adipose tissue results in decreased serum adiponectin and skeletal muscle insulin resistance. *Endocrinology* (2004) **145**:2118–28. doi:10.1210/en.2003-0812
29. Lim JM, Sherling D, Teo CF, Hausman DB, Lin D, Wells L. Defining the regulated secreted proteome of rodent adipocytes upon the induction of insulin resistance. *J Proteome Res* (2008) **7**:1251–63. doi:10.1021/pr7006945
30. Comer FI, Hart GW. O-GlcNAc and the control of gene expression. *Biochim Biophys Acta* (1999) **1473**:161–71. doi:10.1016/S0304-4165(99)00176-2
31. Zachara NE, Hart GW. Cell signaling, the essential role of O-GlcNAc! *Biochim Biophys Acta* (2006) **1761**:599–617. doi:10.1016/j.bbali.2006.04.007
32. Student AK, Hsu RY, Lane MD. Induction of fatty acid synthetase synthesis in differentiating 3T3-L1 preadipocytes. *J Biol Chem* (1980) **255**:4745–50.
33. Harris RB, Mitchell TD, Hebert S. Leptin-induced changes in body composition in high fat-fed mice. *Exp Biol Med (Maywood)* (2003) **228**:24–32.
34. Macauley MS, Bubb AK, Martinez-Fleites C, Davies GJ, Vocadlo DJ. Elevation of global O-GlcNAc levels in 3T3-L1 adipocytes by selective inhibition of O-GlcNAcase does not induce insulin resistance. *J Biol Chem* (2008) **283**:34687–95. doi:10.1074/jbc.M804525200
35. Schneider CA, Rasband WS, Eliceiri KW. NIH Image to ImageJ: 25 years of image analysis. *Nat Methods* (2012) **9**:671–5. doi:10.1038/nmeth.2089
36. Livak KJ, Schmittgen TD. Analysis of relative gene expression data using real-time quantitative PCR and the 2<sup>-ΔΔC<sub>T</sub></sup> method. *Methods* (2001) **25**:402–8. doi:10.1006/meth.2001.1262
37. Kent WJ, Sugnet CW, Furey TS, Roskin KM, Pringle TH, Zahler AM, et al. The human genome browser at UCSC. *Genome Res* (2002) **12**:996–1006. doi:10.1101/gr.229102
38. Hughes JD, Estep PW, Tavazoie S, Church GM. Computational identification of cis-regulatory elements associated with groups of functionally related genes in *Saccharomyces cerevisiae*. *J Mol Biol* (2000) **296**:1205–14. doi:10.1006/jmbi.2000.3519
39. Liu X, Brutlag DL, Liu JS. BioProspector: discovering conserved DNA motifs in upstream regulatory regions of co-expressed genes. *Pac Symp Biocomput* (2001):127–38.
40. Hertz GZ, Stormo GD. Identifying DNA and protein patterns with statistically significant alignments of multiple sequences. *Bioinformatics* (1999) **15**:563–77. doi:10.1093/bioinformatics/15.7.563
41. Olman V, Xu D, Xu Y. CUBIC: identification of regulatory binding sites through data clustering. *J Bioinform Comput Biol* (2003) **1**:21–40. doi:10.1142/S0219720003000162
42. Liu XS, Brutlag DL, Liu JS. An algorithm for finding protein-DNA binding sites with applications to chromatin-immunoprecipitation microarray experiments. *Nat Biotechnol* (2002) **20**:835–9. doi:10.1038/nbt717
43. Bailey TL, Elkan C. Fitting a mixture model by expectation maximization to discover motifs in biopolymers. *Proc Int Conf Intell Syst Mol Biol* (1994) **2**:28–36.
44. Li G, Liu B, Ma Q, Xu Y. A new framework for identifying cis-regulatory motifs in prokaryotes. *Nucleic Acids Res* (2011) **39**:e42. doi:10.1093/nar/gkq948
45. Gupta S, Stamatoyannopoulos JA, Bailey TL, Noble WS. Quantifying similarity between motifs. *Genome Biol* (2007) **8**:R24. doi:10.1186/gb-2007-8-2-r24
46. Loots GG, Ovcharenko I. rVISTA 2.0: evolutionary analysis of transcription factor binding sites. *Nucleic Acids Res* (2004) **32**:W217–21. doi:10.1093/nar/gkh383
47. Brimble S, Edith EW-H, Teo CF, Morris AC, Wells L. The role of the O-GlcNAc modification in regulating eukaryotic gene expression. *Curr Signal Transduct Ther* (2010) **5**:12–24. doi:10.2174/157436210790226465
48. Poulos SP, Dodson MV, Hausman GJ. Cell line models for differentiation: preadipocytes and adipocytes. *Exp Biol Med (Maywood)* (2010) **235**:1185–93. doi:10.1258/ebm.2010.010063
49. MacDougald OA, Hwang CS, Fan H, Lane MD. Regulated expression of the obese gene product (leptin) in white adipose tissue and 3T3-L1 adipocytes. *Proc Natl Acad Sci U S A* (1995) **92**:9034–7. doi:10.1073/pnas.92.20.9034
50. Madiehe AM, Mitchell TD, Harris RB. Hyperleptinemia and reduced TNF- $\alpha$  secretion cause resistance of db/db mice to endotoxin. *Am J Physiol Regul Integr Comp Physiol* (2003) **284**:R763–70.
51. Rosen BS, Cook KS, Yaglom J, Groves DL, Volanakis JE, Damm D, et al. Adipsin and complement factor D activity: an immune-related defect in obesity. *Science* (1989) **244**:1483–7. doi:10.1126/science.2734615
52. Doria A, Patti ME, Kahn CR. The emerging genetic architecture of type 2 diabetes. *Cell Metab* (2008) **8**:186–200. doi:10.1016/j.cmet.2008.08.006
53. Stolerman ES, Florez JC. Genomics of type 2 diabetes mellitus: implications for the clinician. *Nat Rev Endocrinol* (2009) **5**:429–36. doi:10.1038/nrendo.2009.129

54. Muhlhauser BS. Nutritional models of type 2 diabetes mellitus. *Methods Mol Biol* (2009) **560**:19–36. doi:10.1007/978-1-59745-448-3\_2
55. D'Haeseleer P. How does DNA sequence motif discovery work? *Nat Biotechnol* (2006) **24**:959–61. doi:10.1038/nbt0806-959
56. Mason MM, He Y, Chen H, Quon MJ, Reitman M. Regulation of leptin promoter function by Sp1, C/EBP, and a novel factor. *Endocrinology* (1998) **139**:1013–22. doi:10.1210/en.139.3.1013
57. Barth N, Langmann T, Scholmerich J, Schmitz G, Schaffler A. Identification of regulatory elements in the human adipose most abundant gene transcript-1 (apM-1) promoter: role of SP1/SP3 and TNF-alpha as regulatory pathways. *Diabetologia* (2002) **45**:1425–33.
58. Rohrwasser A, Zhang S, Dillon HF, Inoue I, Callaway CW, Hillas E, et al. Contribution of Sp1 to initiation of transcription of angiotensinogen. *J Hum Genet* (2002) **47**:249–56. doi:10.1007/s100380200034
59. Samson SL, Wong NC. Role of Sp1 in insulin regulation of gene expression. *J Mol Endocrinol* (2002) **29**:265–79. doi:10.1677/jme.0.0290265
60. Chung SS, Choi HH, Kim KW, Cho YM, Lee HK, Park KS. Regulation of human resistin gene expression in cell systems: an important role of stimulatory protein 1 interaction with a common promoter polymorphic site. *Diabetologia* (2005) **48**:1150–8. doi:10.1007/s00125-005-1762-y
61. Solomon SS, Majumdar G, Martinez-Hernandez A, Raghov R. A critical role of Sp1 transcription factor in regulating gene expression in response to insulin and other hormones. *Life Sci* (2008) **83**:305–12. doi:10.1016/j.lfs.2008.06.024
62. Chung SS, Kim JH, Park HS, Choi HH, Lee KW, Cho YM, et al. Activation of PPARgamma negatively regulates O-GlcNAcylation of Sp1. *Biochem Biophys Res Commun* (2008) **372**:713–8. doi:10.1016/j.bbrc.2008.05.096
63. Du XL, Edelstein D, Rossetti L, Fantus IG, Goldberg H, Ziyadeh F, et al. Hyperglycemia-induced mitochondrial superoxide overproduction activates the hexosamine pathway and induces plasminogen activator inhibitor-1 expression by increasing Sp1 glycosylation. *Proc Natl Acad Sci U S A* (2000) **97**:12222–6. doi:10.1073/pnas.97.22.12222
64. Yang X, Su K, Roos MD, Chang Q, Paterson AJ, Kudlow JE. O-linkage of N-acetylglucosamine to Sp1 activation domain inhibits its transcriptional capability. *Proc Natl Acad Sci U S A* (2001) **98**:6611–6. doi:10.1073/pnas.111099998
65. Majumdar G, Harmon A, Candelaria R, Martinez-Hernandez A, Raghov R, Solomon SS. O-glycosylation of Sp1 and transcriptional regulation of the calmodulin gene by insulin and glucagon. *Am J Physiol Endocrinol Metab* (2003) **285**:E584–91.
66. Majumdar G, Wright J, Markowitz P, Martinez-Hernandez A, Raghov R, Solomon SS. Insulin stimulates and diabetes inhibits O-linked N-acetylglucosamine transferase and O-glycosylation of Sp1. *Diabetes* (2004) **53**:3184–92. doi:10.2337/diabetes.53.12.3184
67. Goldberg HJ, Whiteside CI, Hart GW, Fantus IG. Posttranslational, reversible O-glycosylation is stimulated by high glucose and mediates plasminogen activator inhibitor-1 gene expression and Sp1 transcriptional activity in glomerular mesangial cells. *Endocrinology* (2006) **147**:222–31. doi:10.1210/en.2006-0523
68. Majumdar G, Harrington A, Hungerford J, Martinez-Hernandez A, Gerling IC, Raghov R, et al. Insulin dynamically regulates calmodulin gene expression by sequential o-glycosylation and phosphorylation of sp1 and its sub-cellular compartmentalization in liver cells. *J Biol Chem* (2006) **281**:3642–50. doi:10.1074/jbc.M511223200
69. Abel ED, Peroni O, Kim JK, Kim YB, Boss O, Hadro E, et al. Adipose-selective targeting of the GLUT4 gene impairs insulin action in muscle and liver. *Nature* (2001) **409**:729–33. doi:10.1038/35055575
70. Carvalho E, Kotani K, Peroni OD, Kahn BB. Adipose-specific overexpression of GLUT4 reverses insulin resistance and diabetes in mice lacking GLUT4 selectively in muscle. *Am J Physiol Endocrinol Metab* (2005) **289**:E551–61. doi:10.1152/ajpendo.00116.2005
71. Yang Q, Graham TE, Mody N, Preitner F, Peroni OD, Zabolotny JM, et al. Serum retinol binding protein 4 contributes to insulin resistance in obesity and type 2 diabetes. *Nature* (2005) **436**:356–62. doi:10.1038/nature03711
72. Rasouli N, Kern PA. Adipocytokines and the metabolic complications of obesity. *J Clin Endocrinol Metab* (2008) **93**:S64–73. doi:10.1210/jc.2008-1613
73. Nagaraju GP, Sharma D. Anti-cancer role of SPARC, an inhibitor of adipogenesis. *Cancer Treat Rev* (2011) **37**:559–66. doi:10.1016/j.ctrv.2010.12.001
74. Reiser J, Adair B, Reinheckel T. Specialized roles for cysteine cathepsins in health and disease. *J Clin Invest* (2010) **120**:3421–31. doi:10.1172/JCI42918
75. Horvath AJ, Irving JA, Rossjohn J, Law RH, Bottomley SP, Quinsey NS, et al. The murine orthologue of human antichymotrypsin: a structural paradigm for clade A3 serpins. *J Biol Chem* (2005) **280**:43168–78. doi:10.1074/jbc.M505598200
76. Antwi K, Hostetter G, Demeure MJ, Katchman BA, Decker GA, Ruiz Y, et al. Analysis of the plasma peptidome from pancreas cancer patients connects a peptide in plasma to overexpression of the parent protein in tumors. *J Proteome Res* (2009) **8**:4722–31. doi:10.1021/pr900414f
77. Katchman BA, Antwi K, Hostetter G, Demeure MJ, Watanabe A, Decker GA, et al. Quiescin sulphydryl oxidase 1 promotes invasion of pancreatic tumor cells mediated by matrix metalloproteinases. *Mol Cancer Res* (2011) **9**:1621–31. doi:10.1158/1541-7786.MCR-11-0018
78. Sun K, Kusminski CM, Scherer PE. Adipose tissue remodeling and obesity. *J Clin Invest* (2011) **121**:2094–101. doi:10.1172/JCI45887
79. MacDougald OA, Lane MD. Transcriptional regulation of gene expression during adipocyte differentiation. *Annu Rev Biochem* (1995) **64**:345–73. doi:10.1146/annurev.bi.64.070195.002021
80. Hwang CS, Loftus TM, Mandrup S, Lane MD. Adipocyte differentiation and leptin expression. *Annu Rev Cell Dev Biol* (1997) **13**:231–59. doi:10.1146/annurev.cellbio.13.1.231
81. Trujillo ME, Scherer PE. Adipose tissue-derived factors: impact on health and disease. *Endocr Rev* (2006) **27**:762–78. doi:10.1210/er.2006-0033
82. Guilherme A, Virbasius JV, Puri V, Czege MP. Adipocyte dysfunctions linking obesity to insulin resistance and type 2 diabetes. *Nat Rev Mol Cell Biol* (2008) **9**:367–77. doi:10.1038/nrm2391
83. Olefsky JM, Glass CK. Macrophages, inflammation, and insulin resistance. *Annu Rev Physiol* (2010) **72**:219–46. doi:10.1146/annurev-physiol-021909-135846
84. Moreno-Aliaga MAJ, Stanhope KL, Gregoire FM, Warden CH, Havel PJ. Effects of inhibiting transcription and protein synthesis on basal and insulin-stimulated leptin gene expression and leptin secretion in cultured rat adipocytes. *Biochem Biophys Res Commun* (2003) **307**:907–14. doi:10.1016/S0006-291X(03)01300-7
85. Lim JM, Wollaston-Hayden EE, Teo CF, Hausman D, Wells L. Quantitative secretome and glycome of primary human adipocytes during insulin resistance. *Clin Proteomics* (2014) **11**:20. doi:10.1186/1559-0275-11-20
86. Chavez C, Boucher J, Monthouel-Kartmann MN, Sage EH, Castan-Laurell I, Valet P, et al. Regulation of secreted protein acidic and rich in cysteine during adipose conversion and adipose tissue hyperplasia. *Obesity (Silver Spring)* (2006) **14**:1890–7. doi:10.1038/oby.2006.220
87. Bessesen DH, Robertson AD, Eckel RH. Weight reduction increases adipose but decreases cardiac LPL in reduced-obese Zucker rats. *Am J Physiol* (1991) **261**:E246–51.
88. Terretz J, Cusin I, Etienne J, Jeanrenaud B. In vivo regulation of adipose tissue lipoprotein lipase in normal rats made hyperinsulinemic and in hyperinsulinemic genetically-obese (fa/fa) rats. *Int J Obes Relat Metab Disord* (1994) **18**:9–15.
89. Preiss-Landl K, Zimmermann R, Hammerle G, Zechner R. Lipoprotein lipase: the regulation of tissue specific expression and its role in lipid and energy metabolism. *Curr Opin Lipidol* (2002) **13**:471–81. doi:10.1097/00041433-200210000-00002
90. Kim SJ, Nian C, McIntosh CH. GIP increases human adipocyte LPL expression through CREB and TORC2-mediated trans-activation of the LPL gene. *J Lipid Res* (2010) **51**:3145–57. doi:10.1194/jlr.M006841
91. Einstein FH, Fishman S, Bauman J, Thompson RF, Huffman DM, Atzmon G, et al. Enhanced activation of a “nutrient-sensing” pathway with age contributes to insulin resistance. *FASEB J* (2008) **22**:3450–7. doi:10.1096/fj.08-109041
92. Zhang P, Klenk ES, Lazzaro MA, Williams LB, Considine RV. Hexosamines regulate leptin production in 3T3-L1 adipocytes through transcriptional mechanisms. *Endocrinology* (2002) **143**:99–106. doi:10.1210/endo.143.1.8568
93. Hawkins M, Barzilai N, Liu R, Hu M, Chen W, Rossetti L. Role of the glucosamine pathway in fat-induced insulin resistance. *J Clin Invest* (1997) **99**:2173–82. doi:10.1172/JCI119390
94. McClain DA, Taylor RP, Soesanto Y, Luo B. Metabolic regulation by the hexosamine biosynthesis/O-linked N-acetylglucosamine pathway. *Curr Signal Transduct Ther* (2010) **5**:3–11. doi:10.2174/157436210790226474

95. Haltiwanger RS, Blomberg MA, Hart GW. Glycosylation of nuclear and cytoplasmic proteins. Purification and characterization of a uridine diphospho-N-acetylglucosamine:polypeptide beta-N-acetylglucosaminyltransferase. *J Biol Chem* (1992) **267**:9005–13.
96. Kreppel LK, Hart GW. Regulation of a cytosolic and nuclear O-GlcNAc transferase. Role of the tetratricopeptide repeats. *J Biol Chem* (1999) **274**:32015–22. doi:10.1074/jbc.274.45.32015
97. Cheung WD, Sakabe K, Housley MP, Dias WB, Hart GW. O-linked beta-N-acetylglucosaminyltransferase substrate specificity is regulated by myosin phosphatase targeting and other interacting proteins. *J Biol Chem* (2008) **283**:33935–41. doi:10.1074/jbc.M806199200
98. Shen DL, Gloster TM, Yuzwa SA, Vocadlo DJ. Insights into O-linked N-acetylglucosamine ([0-9]O-GlcNAc) processing and dynamics through kinetic analysis of O-GlcNAc transferase and O-GlcNAcase activity on protein substrates. *J Biol Chem* (2012) **287**:15395–408. doi:10.1074/jbc.M111.310664
99. Hart GW, Slawson C, Ramirez-Correa G, Lagerlof O. Cross talk between O-GlcNAcylation and phosphorylation: roles in signaling, transcription, and chronic disease. *Annu Rev Biochem* (2011) **80**:825–58. doi:10.1146/annurev-biochem-060608-102511
100. Briggs J, Chamboredon S, Castellazzi M, Kerry JA, Bos TJ. Transcriptional upregulation of SPARC, in response to c-Jun overexpression, contributes to increased motility and invasion of MCF7 breast cancer cells. *Oncogene* (2002) **21**:7077–91. doi:10.1038/sj.onc.1205857
101. Chamboredon S, Briggs J, Vial E, Hurault J, Galvagni F, Oliviero S, et al. v-Jun downregulates the SPARC target gene by binding to the proximal promoter indirectly through Sp1/3. *Oncogene* (2003) **22**:4047–61. doi:10.1038/sj.onc.1206713
102. Xu YZ, Heravi M, Thuraisingam T, Di Marco S, Muanza T, Radzioch D. Brg-1 mediates the constitutive and fenretinide-induced expression of SPARC in mammary carcinoma cells via its interaction with transcription factor Sp1. *Mol Cancer* (2010) **9**:210. doi:10.1186/1476-4598-9-210
103. Hughes TR, Tengku-Muhammad TS, Irvine SA, Ramji DP. A novel role of Sp1 and Sp3 in the interferon-gamma-mediated suppression of macrophage lipoprotein lipase gene transcription. *J Biol Chem* (2002) **277**:11097–106. doi:10.1074/jbc.M106774200
104. Harris SM, Harvey EJ, Hughes TR, Ramji DP. The interferon-gamma-mediated inhibition of lipoprotein lipase gene transcription in macrophages involves casein kinase 2- and phosphoinositide-3-kinase-mediated regulation of transcription factors Sp1 and Sp3. *Cell Signal* (2008) **20**:2296–301. doi:10.1016/j.cellsig.2008.08.016
105. Irvine SA, Foka P, Rogers SA, Mead JR, Ramji DP. A critical role for the Sp1-binding sites in the transforming growth factor-beta-mediated inhibition of lipoprotein lipase gene expression in macrophages. *Nucleic Acids Res* (2005) **33**:1423–34. doi:10.1093/nar/gki280
106. Merkel M, Eckel RH, Goldberg IJ. Lipoprotein lipase: genetics, lipid uptake, and regulation. *J Lipid Res* (2002) **43**:1997–2006. doi:10.1194/jlr.R200015-JLR200
107. Yang WS, Nevin DN, Iwasaki L, Peng R, Brown BG, Brunzell JD, et al. Regulatory mutations in the human lipoprotein lipase gene in patients with familial combined hyperlipidemia and coronary artery disease. *J Lipid Res* (1996) **37**:2627–37.
108. Ehrenborg E, Clee SM, Pimstone SN, Reymer PW, Benlian P, Hoogendijk CF, et al. Ethnic variation and in vivo effects of the -93t ->g promoter variant in the lipoprotein lipase gene. *Arterioscler Thromb Vasc Biol* (1997) **17**:2672–8. doi:10.1161/01.ATV.17.11.2672
109. Radha V, Vimalaswaran KS, Ayyappa KA, Mohan V. Association of lipoprotein lipase gene polymorphisms with obesity and type 2 diabetes in an Asian Indian population. *Int J Obes (Lond)* (2007) **31**:913–8. doi:10.1038/sj.ijo.0803547
110. Smith CE, Tucker KL, Lai CQ, Parnell LD, Lee YC, Ordovas JM. Apolipoprotein A5 and lipoprotein lipase interact to modulate anthropometric measures in Hispanics of Caribbean origin. *Obesity (Silver Spring)* (2010) **18**:327–32. doi:10.1038/oby.2009.216
111. Kastelein JJ, Groenemeyer BE, Hallman DM, Henderson H, Reymer PW, Gagne SE, et al. The Asn9 variant of lipoprotein lipase is associated with the -93G promoter mutation and an increased risk of coronary artery disease. The Regress Study Group. *Clin Genet* (1998) **53**:27–33. doi:10.1034/j.1399-0004.1998.531530106.x
112. Hokanson JE. Functional variants in the lipoprotein lipase gene and risk cardiovascular disease. *Curr Opin Lipidol* (1999) **10**:393–9. doi:10.1097/00041433-199910000-00003
113. Wittrup HH, Andersen RV, Tybjaerg-Hansen A, Jensen GB, Nordestgaard BG. Combined analysis of six lipoprotein lipase genetic variants on triglycerides, high-density lipoprotein, and ischemic heart disease: cross-sectional, prospective, and case-control studies from the Copenhagen City Heart Study. *J Clin Endocrinol Metab* (2006) **91**:1438–45. doi:10.1210/jc.2005-1725
114. Hall S, Chu G, Miller G, Cruickshank K, Cooper JA, Humphries SE, et al. A common mutation in the lipoprotein lipase gene promoter, -93T/G, is associated with lower plasma triglyceride levels and increased promoter activity in vitro. *Arterioscler Thromb Vasc Biol* (1997) **17**:1969–76. doi:10.1161/01.ATV.17.10.1969
115. Yang WS, Deeb SS. Sp1 and Sp3 transactivate the human lipoprotein lipase gene promoter through binding to a CT element: synergy with the sterol regulatory element binding protein and reduced transactivation of a naturally occurring promoter variant. *J Lipid Res* (1998) **39**:2054–64.
116. Wierstra I. Sp1: emerging roles – beyond constitutive activation of TATA-less housekeeping genes. *Biochem Biophys Res Commun* (2008) **372**:1–13. doi:10.1016/j.bbrc.2008.03.074
117. Tan NY, Khachigian LM. Sp1 phosphorylation and its regulation of gene transcription. *Mol Cell Biol* (2009) **29**:2483–8. doi:10.1128/MCB.01828-08
118. Jackson SP, Tjian R. O-glycosylation of eukaryotic transcription factors: implications for mechanisms of transcriptional regulation. *Cell* (1988) **55**:125–33. doi:10.1016/0092-8674(88)90015-3
119. Roos MD, Su K, Baker JR, Kudlow JE. O glycosylation of an Sp1-derived peptide blocks known Sp1 protein interactions. *Mol Cell Biol* (1997) **17**:6472–80.

**Conflict of Interest Statement:** The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.

Received: 28 September 2014; accepted: 05 December 2014; published online: 22 January 2015.

Citation: Wollaston-Hayden EE, Harris RBS, Liu B, Bridger R, Xu Y and Wells L (2015) Global O-GlcNAc levels modulate transcription of the adipocyte secretome during chronic insulin resistance. *Front. Endocrinol.* 5:223. doi: 10.3389/fendo.2014.00223

This article was submitted to *Molecular and Structural Endocrinology*, a section of the journal *Frontiers in Endocrinology*.

Copyright © 2015 Wollaston-Hayden, Harris, Liu, Bridger, Xu and Wells. This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) or licensor are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.